SynthesisCurrent rheumatology reports2016
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
Synthesis in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.The Cochrane database of systematic reviews · 2020Pooled it
- New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis.Current rheumatology reports · 2020Pooled it
- Pooled it
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.The Cochrane database of systematic reviews · 2017Pooled it
- Persistent thrombotic events in a seronegative patient with antiphospholipid syndrome.JAAD case reports · 2026Article
- Trousseau syndrome: management of refractory VTE.Hematology. American Society of Hematology. Education Program · 2024Review
- Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.Journal of clinical medicine · 2024Review
- Article
- Efficacy and safety of Apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study.Frontiers in neurology · 2024Article
- VEXAS Syndrome-Review.Global medical genetics · 2023Review
- Catastrophic Antiphospholipid Syndrome and Renal Failure: An Unexpected Recovery After Three Years on Dialysis.Cureus · 2023Article
- Article
- Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.BMJ case reports · 2022Article
- Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome.Haematologica · 2022Article
- Digital ulcers as presenting symptom of secondary antiphospholipid syndrome.JAAD case reports · 2022Article
- Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Review
- Article
- Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.Journal of thrombosis and thrombolysis · 2021Article
- Respiratory Manifestations in Systemic Lupus Erythematosus.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cornerstone of thrombotic antiphospholipid syndrome (APS) patients' management is to prevent recurrent thrombosis by long-term anticoagulation. PURPOSE OF REVIEW: The purpose of the review is to summarize available literature on direct oral anticoagulants (DOACs) use in APS patients through a systematic review and to determine factors associated with thrombosis recurrence. RECENT
findingsThe recent RAPS trial demonstrated that APS patients treated with rivaroxaban had a significant twofold-increased thrombin potential, suggesting a higher thrombotic risk, in comparison with warfarin users. Furthermore, several reports of APS patients treated with DOACs have raised safety issues. Our systematic review identified 122 published APS patients treated with DOACs; among them, 19 experienced a recurrent thrombosis while on DOACs. Of note, triple positivity (positivity of all three laboratory criteria for APS) was associated with a 3.5-fold increased risk for recurrent thrombosis. In conclusion, DOACs should be used with caution in APS patients and randomized control trials with clinical primary endpoints assessing clinical efficacy and safety are awaited to establish whether the prescription of DOACs could be a safe alternative to warfarin.
Indexed as
Identifiers
27812956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.